Patients with acute or chronic pains often experience a highly unpleasant sensation that sends chills down their spine, agonizing them to a level to resort to solutions with serious side-effects. However, the availability and accessibility of a natural ingredient ‘cannabidiol’, commonly referred to as ‘CBD’ is emerging as a promising substitute for acute and chronic pain management.
Pain Management and its Market
Pain, a primary or secondary symptom for a number of medical ailments is a complex condition in itself. It not only affects the physical well-being of an individual but causes severe mental trauma as well. The intensity of pain varies from person-to-person, as a result of which, the market is flooded with innumerable pharmacological and non-pharmacological solutions. The advancement of technology further fueled the industry, with more pharmaceutical companies pumping in funds to innovate sophisticated therapies to raise life expectancy rates worldwide. The global market for pain management accounted for $58,577 million in 2016 and is speculated to touch $77,131 million by 2023. However, the availability of alternate generic medicines and opioids hinders the growth of sophisticated technologies and therapies in the segment.
Opioid Crisis Creates Room for Innovation
Painkillers and opioids being the only effective solution left to treat acute and chronic pains have been widely abused and over-prescribed. As a result, the world is going through a ‘drug-abuse’ crisis as a majority of the painkillers and opioids cause physical and psychological dependence over a period of time. The market is crying out for innovative options to cater to the rising need for better solutions.
Keeping this into account, the pharmaceutical and biotechnological giants had been looking for better alternatives to revive the market. Thanks to the legalization of medical cannabis in certain parts of the world, these firms have got an opportunity to innovate novel drugs from a 100 percent natural plant extract with an effective, non-toxic and no-dependence nature.
Researchers from around the world have proved the efficacy and reliability of cannabinoids in treating acute and chronic pains without causing any kind of dependency. The cannabidiol component of cannabinoid works in synergy with the endogenous cannabinoid system of our body with two major receptors CB1 and CB2. While CB2 receptors work in tandem with the immune system, CB1 receptors are a common feature of the central nervous system. These CB1 receptor are known for altering the neurotransmitters of the brain, producing a psychoactive effect while maintaining the homeostasis of the body. In other words, the release of these neurotransmitters originate sensations like pleasure, pain-tolerance, appetite, memory, and concentration. CB2 receptors, on the other hand, modulate the pain sensation by controlling the immune system.
Presently, companies like Isodiol International Inc., Kalytera Therapeutics Inc., Zynerba Pharmaceuticals, Axim Biotechnologies, Insys Therapeutics and so on are cutting a major share of this ever-emerging market by bringing natural yet novel therapies to the shelves.
In a nutshell, research studies conducted in controlled environments to understand the effectiveness and safety of the cannabinoids that claim to improve the unpleasant sensation without any harmful effect of physical or mental well-being of the patient.